{"transactions":[{"id":4636923,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-07T20:02:00.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":23463,"price":7.1977,"value":168879.6351,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1519606,"source":{"system":"sec-edgar","filing":"0001193125-26-416953","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526416953/ownership.xml","form_type":"4"}},{"id":4635912,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-10-06T20:02:57.000Z","date":"2026-10-05","kind":"sale","planned":false,"acquired":false,"shares":10340,"price":6.8372,"value":70696.648,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":312744,"source":{"system":"sec-edgar","filing":"0001193125-26-415531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526415531/ownership.xml","form_type":"4"}},{"id":4635910,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Compliance Officer"}}],"security":"Common Stock","published_at":"2026-10-06T20:02:30.000Z","date":"2026-10-05","kind":"sale","planned":false,"acquired":false,"shares":8370,"price":6.8372,"value":57227.364,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":366159,"source":{"system":"sec-edgar","filing":"0001193125-26-415529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526415529/ownership.xml","form_type":"4"}},{"id":4635909,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-10-06T20:02:00.000Z","date":"2026-10-05","kind":"sale","planned":false,"acquired":false,"shares":1099,"price":6.8372,"value":7514.0828,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":169848,"source":{"system":"sec-edgar","filing":"0001193125-26-415528","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065633/000119312526415528/ownership.xml","form_type":"4"}},{"id":4635908,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-06T20:01:36.000Z","date":"2026-10-05","kind":"sale","planned":false,"acquired":false,"shares":61696,"price":6.8372,"value":421827.8912,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":1543069,"source":{"system":"sec-edgar","filing":"0001193125-26-415527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526415527/ownership.xml","form_type":"4"}},{"id":4618197,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-15T20:44:04.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":315000,"derivative":{"exercise_price":8.91,"expiration_date":"2036-09-14","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193125-26-392025","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526392025/ownership.xml","form_type":"4"}},{"id":4618196,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T20:44:04.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":1604765,"source":{"system":"sec-edgar","filing":"0001193125-26-392025","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526392025/ownership.xml","form_type":"4"}},{"id":4617557,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-15T00:07:15.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":155000,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001193125-26-391012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526391012/ownership.xml","form_type":"4"}},{"id":4617556,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-15T00:07:15.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":1494765,"source":{"system":"sec-edgar","filing":"0001193125-26-391012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526391012/ownership.xml","form_type":"4"}},{"id":4617470,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T22:46:48.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the grant of a stock option to Laura Stoppel in connection with her service on the Issuer's board of directors. The shares subject to the option will vest on the earlier of September 10, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the\nAdviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001231919-26-001173","document":"form4-09142026_100941.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883840/000123191926001173/form4-09142026_100941.xml","form_type":"4"}},{"id":4616820,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:05:20.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000119312526390558/ownership.xml","form_type":"4"}},{"id":4616793,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":11510,"kind":"person","name":"Sorg Elaine K.","position":1,"cik":"0001832571","reported_name":"Sorg Elaine K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:04:39.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832571/000119312526390540/ownership.xml","form_type":"4"}},{"id":4616792,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":59557,"kind":"person","name":"HOUGEN ELIZABETH L","position":1,"cik":"0001074773","reported_name":"HOUGEN ELIZABETH L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:04:12.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390534","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526390534/ownership.xml","form_type":"4"}},{"id":4616790,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":16508,"kind":"person","name":"DANIELS BRIAN","position":1,"cik":"0001428698","reported_name":"DANIELS BRIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:03:37.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526390531/ownership.xml","form_type":"4"}},{"id":4616785,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:03:07.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390527","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000119312526390527/ownership.xml","form_type":"4"}},{"id":4616779,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:02:40.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390524","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526390524/ownership.xml","form_type":"4"}},{"id":4616448,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-11T22:37:47.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":135000,"derivative":{"exercise_price":10.79,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001193125-26-389514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389514/ownership.xml","form_type":"4"}},{"id":4616447,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-11T22:37:47.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":122500,"source":{"system":"sec-edgar","filing":"0001193125-26-389514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389514/ownership.xml","form_type":"4"}},{"id":4616446,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-11T22:36:49.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":120000,"derivative":{"exercise_price":10.79,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193125-26-389512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389512/ownership.xml","form_type":"4"}},{"id":4616445,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:36:49.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":323084,"source":{"system":"sec-edgar","filing":"0001193125-26-389512","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389512/ownership.xml","form_type":"4"}},{"id":4616444,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Compliance Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-11T22:36:05.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":135000,"derivative":{"exercise_price":10.79,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001193125-26-389511","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389511/ownership.xml","form_type":"4"}},{"id":4616443,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Compliance Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:36:05.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":374529,"source":{"system":"sec-edgar","filing":"0001193125-26-389511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389511/ownership.xml","form_type":"4"}},{"id":4616442,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-11T22:35:23.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":85000,"derivative":{"exercise_price":10.79,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001193125-26-389510","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065633/000119312526389510/ownership.xml","form_type":"4"}},{"id":4616441,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:35:23.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":170947,"source":{"system":"sec-edgar","filing":"0001193125-26-389510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065633/000119312526389510/ownership.xml","form_type":"4"}},{"id":4613240,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-09T20:02:44.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":23429,"price":10.9158,"value":255746.2782,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $10.9158, and the range of prices were between $10.72 and $11.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1449765,"source":{"system":"sec-edgar","filing":"0001193125-26-386431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526386431/ownership.xml","form_type":"4"}},{"id":3604904,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T22:29:11.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the grant of a stock option to Laura Stoppel pursuant to the Issuer's non-employee director compensation policy. The shares subject to the option will vest on the earlier of September 8, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the\nAdviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001231919-26-001152","document":"form4-09082026_100904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883840/000123191926001152/form4-09082026_100904.xml","form_type":"4"}},{"id":3575944,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:58:07.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000119312526385419/ownership.xml","form_type":"4"}},{"id":3575262,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":11510,"kind":"person","name":"Sorg Elaine K.","position":1,"cik":"0001832571","reported_name":"Sorg Elaine K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:57:33.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832571/000119312526385418/ownership.xml","form_type":"4"}},{"id":3574729,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":59557,"kind":"person","name":"HOUGEN ELIZABETH L","position":1,"cik":"0001074773","reported_name":"HOUGEN ELIZABETH L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:56:55.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526385416/ownership.xml","form_type":"4"}},{"id":3574215,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":16508,"kind":"person","name":"DANIELS BRIAN","position":1,"cik":"0001428698","reported_name":"DANIELS BRIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:56:22.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385414","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526385414/ownership.xml","form_type":"4"}},{"id":3573987,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:55:56.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385412","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000119312526385412/ownership.xml","form_type":"4"}},{"id":3573372,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":64703,"kind":"person","name":"MOORE ALISON","position":1,"cik":"0001754937","reported_name":"MOORE ALISON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:55:19.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526385409/ownership.xml","form_type":"4"}},{"id":4321,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:04:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":10366,"price":11.1555,"value":115637.913,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0301 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":283084,"source":{"system":"sec-edgar","filing":"0001193125-26-383625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526383625/ownership.xml","form_type":"4"}},{"id":4320,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Compliance Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:03:38.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":8391,"price":11.1555,"value":93605.8005,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0350 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":329529,"source":{"system":"sec-edgar","filing":"0001193125-26-383621","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526383621/ownership.xml","form_type":"4"}},{"id":4312,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:03:14.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":1100,"price":11.1556,"value":12271.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":140947,"source":{"system":"sec-edgar","filing":"0001193125-26-383619","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065633/000119312526383619/ownership.xml","form_type":"4"}},{"id":4311,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:02:40.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":61888,"price":11.1555,"value":690391.584,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0270 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1473194,"source":{"system":"sec-edgar","filing":"0001193125-26-383618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1909362/000119312526383618/ownership.xml","form_type":"4"}},{"id":672078,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-31T23:06:27.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":false,"shares":5306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months."}],"balance_after":74265,"derivative":{"exercise_price":1.92,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":5306},"source":{"system":"sec-edgar","filing":"0001193125-26-377207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526377207/ownership.xml","form_type":"4"}},{"id":672077,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-31T23:06:27.000Z","date":"2026-08-27","kind":"sale","planned":true,"acquired":false,"shares":8222,"price":12.0087,"value":98735.5314,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.0087, and the range of prices were between $12.00 and $12.05, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":142047,"source":{"system":"sec-edgar","filing":"0001193125-26-377207","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526377207/ownership.xml","form_type":"4"}},{"id":672076,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-31T23:06:27.000Z","date":"2026-08-27","kind":"exercise","planned":true,"acquired":true,"shares":5306,"price":1.92,"value":10187.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026."}],"balance_after":150269,"source":{"system":"sec-edgar","filing":"0001193125-26-377207","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526377207/ownership.xml","form_type":"4"}},{"id":681509,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-20T01:00:36.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":false,"shares":429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of 1/36th per month over the following 36 months."}],"balance_after":79571,"derivative":{"exercise_price":1.92,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":429},"source":{"system":"sec-edgar","filing":"0001193125-26-357383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526357383/ownership.xml","form_type":"4"}},{"id":681508,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-20T01:00:36.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":429,"price":12,"value":5148.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026."}],"balance_after":144963,"source":{"system":"sec-edgar","filing":"0001193125-26-357383","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526357383/ownership.xml","form_type":"4"}},{"id":681507,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-20T01:00:36.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":true,"shares":429,"price":1.92,"value":823.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026."}],"balance_after":145392,"source":{"system":"sec-edgar","filing":"0001193125-26-357383","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526357383/ownership.xml","form_type":"4"}},{"id":700015,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-31T21:13:03.000Z","date":"2026-07-31","kind":"purchase","planned":false,"acquired":true,"shares":24944,"price":9.93,"value":247693.92,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.82 to $9.97 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":17329570,"source":{"system":"sec-edgar","filing":"0001231919-26-000817","document":"form4-07312026_090755.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000817/form4-07312026_090755.xml","form_type":"4"}},{"id":700014,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-31T21:13:03.000Z","date":"2026-07-29","kind":"purchase","planned":false,"acquired":true,"shares":20824,"price":9.99,"value":208031.76,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.84 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":17304626,"source":{"system":"sec-edgar","filing":"0001231919-26-000817","document":"form4-07312026_090755.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000817/form4-07312026_090755.xml","form_type":"4"}},{"id":702247,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-28T21:24:04.000Z","date":"2026-07-24","kind":"purchase","planned":false,"acquired":true,"shares":41319,"price":9.99,"value":412776.81,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.96 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":17283802,"source":{"system":"sec-edgar","filing":"0001231919-26-000808","document":"form4-07282026_090756.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000808/form4-07282026_090756.xml","form_type":"4"}},{"id":704031,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T01:22:32.000Z","date":"2026-07-23","kind":"purchase","planned":false,"acquired":true,"shares":59880,"price":9.96,"value":596404.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.40 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":17242483,"source":{"system":"sec-edgar","filing":"0001231919-26-000791","document":"form4-07242026_010725.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000791/form4-07242026_010725.xml","form_type":"4"}},{"id":704030,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T01:22:32.000Z","date":"2026-07-22","kind":"purchase","planned":false,"acquired":true,"shares":84124,"price":9.93,"value":835351.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.72 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":17182603,"source":{"system":"sec-edgar","filing":"0001231919-26-000791","document":"form4-07242026_010725.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000791/form4-07242026_010725.xml","form_type":"4"}},{"id":704029,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T01:22:32.000Z","date":"2026-07-21","kind":"purchase","planned":false,"acquired":true,"shares":120582,"price":9.55,"value":1151558.1,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 to $10.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":17098479,"source":{"system":"sec-edgar","filing":"0001231919-26-000791","document":"form4-07242026_010725.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000791/form4-07242026_010725.xml","form_type":"4"}},{"id":704028,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T01:21:06.000Z","date":"2026-07-13","kind":"purchase","planned":false,"acquired":true,"shares":6522,"price":8.94,"value":58306.68,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A amends the Form 4 filed on July 14, 2026 to correct the number of shares purchased, which were reported as 6,552, due to a clerical error."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Fund."}],"balance_after":16817543,"source":{"system":"sec-edgar","filing":"0001231919-26-000790","document":"form4a-07242026_010759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000790/form4a-07242026_010759.xml","form_type":"4/A","original_submission_date":"2026-07-14"}},{"id":705818,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-20T22:08:52.000Z","date":"2026-07-17","kind":"purchase","planned":false,"acquired":true,"shares":7882,"price":8.95,"value":70543.9,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16977927,"source":{"system":"sec-edgar","filing":"0001231919-26-000774","document":"form4-07202026_100743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000774/form4-07202026_100743.xml","form_type":"4"}},{"id":705817,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-20T22:08:52.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":152472,"price":8.93,"value":1361574.96,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.79 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16970045,"source":{"system":"sec-edgar","filing":"0001231919-26-000774","document":"form4-07202026_100743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000774/form4-07202026_100743.xml","form_type":"4"}},{"id":709830,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-14T23:00:23.000Z","date":"2026-07-13","kind":"purchase","planned":false,"acquired":true,"shares":6552,"price":8.94,"value":58574.88,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16817573,"source":{"system":"sec-edgar","filing":"0001231919-26-000764","document":"form4-07142026_110714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000764/form4-07142026_110714.xml","form_type":"4"}},{"id":709829,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-14T23:00:23.000Z","date":"2026-07-10","kind":"purchase","planned":false,"acquired":true,"shares":15102,"price":8.97,"value":135464.94,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16811021,"source":{"system":"sec-edgar","filing":"0001231919-26-000764","document":"form4-07142026_110714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000764/form4-07142026_110714.xml","form_type":"4"}},{"id":724130,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T20:20:33.000Z","date":"2026-06-26","kind":"purchase","planned":false,"acquired":true,"shares":1876,"price":8.98,"value":16846.48,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16795919,"source":{"system":"sec-edgar","filing":"0001231919-26-000711","document":"form4-06292026_080626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000711/form4-06292026_080626.xml","form_type":"4"}},{"id":724129,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-29T20:20:33.000Z","date":"2026-06-25","kind":"purchase","planned":false,"acquired":true,"shares":31000,"price":8.88,"value":275280.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.62 to $8.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16794043,"source":{"system":"sec-edgar","filing":"0001231919-26-000711","document":"form4-06292026_080626.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000711/form4-06292026_080626.xml","form_type":"4"}},{"id":736330,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:08:15.000Z","date":"2026-06-16","kind":"purchase","planned":false,"acquired":true,"shares":124893,"price":8.89,"value":1110298.77,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.63 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16763043,"source":{"system":"sec-edgar","filing":"0001231919-26-000656","document":"form4-06162026_100608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000656/form4-06162026_100608.xml","form_type":"4"}},{"id":736329,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:08:15.000Z","date":"2026-06-15","kind":"purchase","planned":false,"acquired":true,"shares":15414,"price":8.99,"value":138571.86,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.96 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16638150,"source":{"system":"sec-edgar","filing":"0001231919-26-000656","document":"form4-06162026_100608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000656/form4-06162026_100608.xml","form_type":"4"}},{"id":736328,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T22:08:15.000Z","date":"2026-06-12","kind":"purchase","planned":false,"acquired":true,"shares":391019,"price":8.57,"value":3351032.83,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.31 to $8.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16622736,"source":{"system":"sec-edgar","filing":"0001231919-26-000656","document":"form4-06162026_100608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000656/form4-06162026_100608.xml","form_type":"4"}},{"id":741805,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:36:33.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":548580,"price":7.91,"value":4339267.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.605 to $8.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":16231717,"source":{"system":"sec-edgar","filing":"0001231919-26-000625","document":"form4-06112026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000625/form4-06112026_110625.xml","form_type":"4"}},{"id":741804,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:36:33.000Z","date":"2026-06-10","kind":"purchase","planned":false,"acquired":true,"shares":103,"price":7,"value":721.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":15683137,"source":{"system":"sec-edgar","filing":"0001231919-26-000625","document":"form4-06112026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000625/form4-06112026_110625.xml","form_type":"4"}},{"id":741803,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:36:33.000Z","date":"2026-06-09","kind":"purchase","planned":false,"acquired":true,"shares":479039,"price":6.91,"value":3310159.49,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.77 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":15683034,"source":{"system":"sec-edgar","filing":"0001231919-26-000625","document":"form4-06112026_110625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000625/form4-06112026_110625.xml","form_type":"4"}},{"id":760407,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:34:23.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":347222,"price":11.52,"value":3999997.44,"ownership":{"direct":false,"nature":"By GC Cell Corporation"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein."}],"balance_after":1607734,"source":{"system":"sec-edgar","filing":"0001931382-26-000007","document":"form4-05282026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000193138226000007/form4-05282026_080518.xml","form_type":"4"}},{"id":760406,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":43553,"kind":"organization","name":"GC Corp.","position":1,"cik":"0001931382","reported_name":"GC Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":43554,"kind":"organization","name":"GC Cell Corp","position":2,"cik":"0001931891","reported_name":"GC Cell Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:34:23.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":1085069,"price":11.52,"value":12499994.88,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by GC Corp., except to the extent of any pecuniary interest therein."}],"balance_after":4391969,"source":{"system":"sec-edgar","filing":"0001931382-26-000007","document":"form4-05282026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1931891/000193138226000007/form4-05282026_080518.xml","form_type":"4"}},{"id":772602,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Common Stock","published_at":"2026-05-20T01:52:54.000Z","date":"2026-05-19","kind":"sale","planned":false,"acquired":false,"shares":3095,"price":9.0078,"value":27879.141,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7447 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":148228,"source":{"system":"sec-edgar","filing":"0001193125-26-231510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312526231510/ownership.xml","form_type":"4"}},{"id":772230,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-05-20T01:52:09.000Z","date":"2026-05-19","kind":"sale","planned":false,"acquired":false,"shares":7002,"price":9.0078,"value":63072.6156,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7421 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":293450,"source":{"system":"sec-edgar","filing":"0001193125-26-231509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526231509/ownership.xml","form_type":"4"}},{"id":772229,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Compliance Officer"}}],"security":"Common Stock","published_at":"2026-05-20T01:51:19.000Z","date":"2026-05-19","kind":"sale","planned":false,"acquired":false,"shares":8790,"price":9.0078,"value":79178.562,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7439 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":337920,"source":{"system":"sec-edgar","filing":"0001193125-26-231508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526231508/ownership.xml","form_type":"4"}},{"id":772228,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-20T01:50:38.000Z","date":"2026-05-19","kind":"sale","planned":false,"acquired":false,"shares":7037,"price":9.0076,"value":63386.4812,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.0076, and the range of prices were between $8.7404 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":144963,"source":{"system":"sec-edgar","filing":"0001193125-26-231507","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526231507/ownership.xml","form_type":"4"}},{"id":772227,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-20T01:50:02.000Z","date":"2026-05-19","kind":"sale","planned":false,"acquired":false,"shares":27116,"price":9.0077,"value":244252.7932,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1535082,"source":{"system":"sec-edgar","filing":"0001193125-26-231506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526231506/ownership.xml","form_type":"4"}},{"id":772226,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-05-19T12:11:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":232500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents stock option award granted under the Issuer's 2025 Inducement Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months."}],"balance_after":232500,"derivative":{"exercise_price":9.22,"expiration_date":"2036-05-17","underlying":"Common Stock","underlying_shares":232500},"source":{"system":"sec-edgar","filing":"0001193125-26-229727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229727/ownership.xml","form_type":"4"}},{"id":772225,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Common Stock","published_at":"2026-05-19T12:11:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan."}],"balance_after":77500,"source":{"system":"sec-edgar","filing":"0001193125-26-229727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229727/ownership.xml","form_type":"4"}},{"id":780909,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-05-13T21:45:56.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":2170138,"price":11.5199,"value":24999772.7462,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by the Fund."}],"balance_after":2170138,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":2170138},"source":{"system":"sec-edgar","filing":"0001231919-26-000491","document":"form4-05132026_090548.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000491/form4-05132026_090548.xml","form_type":"4"}},{"id":780908,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":4,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":5,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":6,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-13T21:45:56.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":6510416,"price":11.52,"value":74999992.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by the Fund."}],"balance_after":15203995,"source":{"system":"sec-edgar","filing":"0001231919-26-000491","document":"form4-05132026_090548.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000123191926000491/form4-05132026_090548.xml","form_type":"4"}},{"id":851136,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":61764,"kind":"person","name":"Huston Thad Allen","position":1,"cik":"0001706052","reported_name":"Huston Thad Allen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-10T20:47:06.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan."}],"balance_after":220000,"source":{"system":"sec-edgar","filing":"0001193125-26-100294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526100294/ownership.xml","form_type":"4"}},{"id":893542,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":11510,"kind":"person","name":"Sorg Elaine K.","position":1,"cik":"0001832571","reported_name":"Sorg Elaine K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-02-20T02:50:03.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares vested following the grant date, with the remaining shares vesting monthly over an additional two years following February 18, 2026."}],"balance_after":27500,"derivative":{"exercise_price":4.15,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001193125-26-060074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526060074/ownership.xml","form_type":"4"}},{"id":897453,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Common Stock","published_at":"2026-02-18T23:51:15.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1521,"price":4,"value":6084.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":151323,"source":{"system":"sec-edgar","filing":"0001193125-26-057674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312526057674/ownership.xml","form_type":"4"}},{"id":897452,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Common Stock","published_at":"2026-02-18T23:51:15.000Z","date":"2026-02-15","kind":"grant","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":152844,"source":{"system":"sec-edgar","filing":"0001193125-26-057674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312526057674/ownership.xml","form_type":"4"}},{"id":897102,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:50:20.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2187,"price":4,"value":8748.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":300452,"source":{"system":"sec-edgar","filing":"0001193125-26-057672","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057672/ownership.xml","form_type":"4"}},{"id":897101,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:50:20.000Z","date":"2026-02-15","kind":"grant","planned":false,"acquired":true,"shares":117300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":302639,"source":{"system":"sec-edgar","filing":"0001193125-26-057672","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057672/ownership.xml","form_type":"4"}},{"id":897100,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Secy, Compliance Off"}}],"security":"Common Stock","published_at":"2026-02-18T23:49:20.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":3515,"price":4,"value":14060.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":346710,"source":{"system":"sec-edgar","filing":"0001193125-26-057669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057669/ownership.xml","form_type":"4"}},{"id":897099,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Secy, Compliance Off"}}],"security":"Common Stock","published_at":"2026-02-18T23:49:20.000Z","date":"2026-02-15","kind":"grant","planned":false,"acquired":true,"shares":117300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":350225,"source":{"system":"sec-edgar","filing":"0001193125-26-057669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057669/ownership.xml","form_type":"4"}},{"id":897096,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10000,"kind":"person","name":"Banerjee Subhashis","position":1,"cik":"0002065633","reported_name":"Banerjee Subhashis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:48:47.000Z","date":"2026-02-15","kind":"grant","planned":false,"acquired":true,"shares":102000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":152000,"source":{"system":"sec-edgar","filing":"0001193125-26-057668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057668/ownership.xml","form_type":"4"}},{"id":897098,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-18T23:48:01.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":14600,"price":4,"value":58400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":1562198,"source":{"system":"sec-edgar","filing":"0001193125-26-057667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057667/ownership.xml","form_type":"4"}},{"id":897097,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-18T23:48:01.000Z","date":"2026-02-15","kind":"grant","planned":false,"acquired":true,"shares":366850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":1576798,"source":{"system":"sec-edgar","filing":"0001193125-26-057667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057667/ownership.xml","form_type":"4"}},{"id":969598,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-16T02:19:28.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":3187,"price":6,"value":19122.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024."}],"balance_after":1209948,"source":{"system":"sec-edgar","filing":"0001193125-25-319696","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525319696/ownership.xml","form_type":"4"}},{"id":971523,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:21:14.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10259,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":13.47,"expiration_date":"2034-05-01","underlying":"Common Stock","underlying_shares":10259},"source":{"system":"sec-edgar","filing":"0001193125-25-317983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312525317983/ownership.xml","form_type":"4"}},{"id":971522,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:21:14.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11399,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts."}],"balance_after":0,"derivative":{"exercise_price":5.18,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":11399},"source":{"system":"sec-edgar","filing":"0001193125-25-317983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312525317983/ownership.xml","form_type":"4"}},{"id":971521,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:21:14.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14819,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":14819},"source":{"system":"sec-edgar","filing":"0001193125-25-317983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312525317983/ownership.xml","form_type":"4"}},{"id":971520,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:21:14.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12539,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares vested on January 1, 2024, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":12539},"source":{"system":"sec-edgar","filing":"0001193125-25-317983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312525317983/ownership.xml","form_type":"4"}},{"id":971519,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:21:14.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18239,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on October 22, 2021, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.14,"expiration_date":"2030-11-02","underlying":"Common Stock","underlying_shares":18239},"source":{"system":"sec-edgar","filing":"0001193125-25-317983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312525317983/ownership.xml","form_type":"4"}},{"id":971518,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":46037,"kind":"person","name":"Raymon Heather","position":1,"cik":"0002028466","reported_name":"Raymon Heather","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Research and Development"}}],"security":"Common Stock","published_at":"2025-12-13T00:21:14.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":67253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."}],"balance_after":106844,"source":{"system":"sec-edgar","filing":"0001193125-25-317983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028466/000119312525317983/ownership.xml","form_type":"4"}},{"id":971343,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":13.47,"expiration_date":"2034-05-01","underlying":"Common Stock","underlying_shares":20519},"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":971342,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9119,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting is monthly over a 48-month period starting May 24, 2023 in equal monthly amounts."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":9119},"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":971341,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":77519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on December 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":77519},"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":971340,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":107156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."}],"balance_after":185339,"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":971339,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Secy, Compliance Off"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:19:34.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":13.47,"expiration_date":"2034-05-01","underlying":"Common Stock","underlying_shares":20519},"source":{"system":"sec-edgar","filing":"0001193125-25-317981","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317981/ownership.xml","form_type":"4"}},{"id":971338,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Secy, Compliance Off"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:19:34.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14202,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts."}],"balance_after":0,"derivative":{"exercise_price":5.18,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14202},"source":{"system":"sec-edgar","filing":"0001193125-25-317981","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317981/ownership.xml","form_type":"4"}},{"id":971337,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Secy, Compliance Off"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:19:34.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9119,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting is monthly over a 48-month period starting May 24, 2023 in equal monthly amounts."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":9119},"source":{"system":"sec-edgar","filing":"0001193125-25-317981","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317981/ownership.xml","form_type":"4"}},{"id":971336,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Secy, Compliance Off"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:19:34.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41039,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":41039},"source":{"system":"sec-edgar","filing":"0001193125-25-317981","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317981/ownership.xml","form_type":"4"}},{"id":971335,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10003,"kind":"person","name":"Bush Jennifer","position":1,"cik":"0001621152","reported_name":"Bush Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, CLO, Secy, Compliance Off"}}],"security":"Common Stock","published_at":"2025-12-13T00:19:34.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":84877,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."}],"balance_after":232925,"source":{"system":"sec-edgar","filing":"0001193125-25-317981","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317981/ownership.xml","form_type":"4"}},{"id":971334,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":9999,"kind":"person","name":"Aslan Fred","position":1,"cik":"0001909362","reported_name":"Aslan Fred","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:19:00.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":319331,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":12,"expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":319331},"source":{"system":"sec-edgar","filing":"0001193125-25-317980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317980/ownership.xml","form_type":"4"}}],"next_cursor":"2025-12-13T00:19:00.000000Z,971334"}